Remote monitoring in CIDP (RMCIDP)

  • Research type

    Research Study

  • Full title

    Exploring the feasibility of remote monitoring in adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  • IRAS ID

    367075

  • Contact name

    Sherryl Chatfield

  • Contact email

    sherryl.chatfield@stgeorges.nhs.uk

  • Sponsor organisation

    St George's University Hospitals NHS Foundation Trust

  • Duration of Study in the UK

    1 years, 0 months, 1 days

  • Research summary

    Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a long-term condition affecting the peripheral nerves. This a relapsing and remitting condition treated with regular infusions of immunoglobulin. Because the disease can improve or worsen over time, it can be time consuming to determine the best interval between immunoglobulin infusions for each individual. If appointments happen too often, patients suffer unnecessary visits; too rarely, and their symptoms may worsen. This uncertainty also places pressure on healthcare resources — especially given rising demand, high costs, and inconsistent supply of immunoglobulin.

    People living with CIDP report that fatigue and weakness are their most troublesome and important symptoms to treat. Frequent hospital assessments are burdensome, and because symptom changes can happen between scheduled visits (every 3–12 weeks), some worsening or recovery may remain undetected.

    The proposed study aims to explore whether remote monitoring — using patient-reported questionnaires, wearable sensors, and handheld strength measurements — could help track symptom changes more continuously from home. If fluctuations in functional changes could be monitored reliably, infusions could be scheduled more accurately: giving treatment when needed, avoiding unnecessary hospital appointments, and reducing patient burden.

    This is a feasibility study, where participants will have additional monitoring alongside their routine assessments, immunoglobulin infusions and clinical care. This study aiming to recruit 10 participants with CIDP, eight during annual cessation trials and two starting on IVIG. Each participant will be recruited for approximately six months, and will be asked to complete questionnaires and strength tests at home throughout this time. They will also wear sensors on their wrist and ankle each day to record their activity. During planned hospital visits for immunoglobulin infusions participants will undergo clinical assessments as per routine clinical care.

  • REC name

    East Midlands - Leicester Central Research Ethics Committee

  • REC reference

    26/EM/0055

  • Date of REC Opinion

    15 Apr 2026

  • REC opinion

    Further Information Favourable Opinion